Table 1:
Patient characteristics overall and by study
| Characteristics | Overall N=384 |
VUMC N=217 |
UPMC N=167 |
P-Value |
|---|---|---|---|---|
|
| ||||
| N (%) | N (%) | N (%) | ||
| Age at Diagnosis (years) | ||||
| Median (IQR) | 57 (51–64) | 57 (50–65) | 57 (51–63) | 0.968 |
| Year of Cancer Diagnosis | ||||
| 1980–1990 | 5 (1.30) | 0 (0.0) | 5 (2.99) | |
| 1991–2000 | 17 (4.43) | 0 (0.0) | 17 (10.18) | |
| 2001–2010 | 95 (24.74) | 90 (41.47) | 5 (2.99) | |
| 2011–2018 | 267 (69.53) | 127 (58.53) | 140 (83.83) | <0.001 |
| Gender | ||||
| Male | 343 (89.32) | 196 (90.32) | 147 (88.02) | |
| Female | 41 (10.68) | 21 (9.68) | 20 (11.98) | 0.470 |
| Race1 | ||||
| Caucasian | 375 (97.66) | 210 (96.77) | 165 (98.80) | |
| African American | 6 (1.56) | 4 (1.84) | 2 (1.20) | 0.272 |
| Smoking History2 | ||||
| No | 128 (33.33) | 81 (37.33) | 47 (28.14) | |
| Yes | 251 (65.36) | 134 (61.75) | 117 (70.06) | 0.032 |
| Pack years3 | ||||
| Median (IQR) | 30 (15–45) | 30 (15–48) | 30 (13–42) | 0.926 |
| Stage (AJCC 8th Edition)4,5 | ||||
| I | 262 (68.23) | 136 (62.67) | 126 (75.45) | |
| II | 69 (17.97) | 46 (21.20) | 23 (13.77) | |
| III | 38 (9.90) | 21 (9.68) | 17 (10.18) | |
| IV | 2 (0.52) | 2 (0.92) | 0 (0.00) | 0.009 |
| Treatment6 | ||||
| Surgery + Radiation + Chemo | 126 (32.81) | 74 (34.10) | 52 (31.14) | |
| Radiation + Chemo | 107 (27.86) | 91 (41.94) | 16 (9.58) | |
| Surgery Only | 55 (14.32) | 32 (14.75) | 23 (13.77) | |
| Surgery + Radiation | 62 (16.15) | 14 (6.45) | 48 (28.74) | |
| Other7 | 32 (8.33) | 5 (2.30) | 27 (16.17) | <0.001 |
| p16 Status8 | ||||
| Negative | 4 (1.04) | 4 (1.84) | 0 (0.0) | |
| Positive | 366 (95.31) | 211 (97.24) | 155 (92.81) | |
| Equivocal | 2 (0.52) | 2 (0.92) | 0 (0.0) | <0.001 |
| HPV16 Sublineage | ||||
| A1 | 215 (55.99) | 114 (52.53) | 101 (60.48) | |
| A2 | 107 (27.86) | 64 (29.49) | 43 (25.75) | |
| A3 | 3 (0.78) | 3 (1.38) | 0 (0.0) | |
| A4 | 22 (5.73) | 14 (6.45) | 8 (4.79) | |
| B1 | 1 (0.26) | 1 (0.46) | 0 (0.0) | |
| C1 | 6 (1.56) | 4 (1.84) | 2 (1.20) | |
| D1 | 1 (0.26) | 1 (0.46) | 0 (0.0) | |
| D2 | 2 (0.52) | 0 (0.0) | 2 (1.20) | |
| D3 | 25 (6.51) | 14 (6.45) | 11 (6.59) | |
| D4 | 2 (0.52) | 2 (0.92) | 0 (0.0) | 0.332 |
Race missing for 3 VUMC patients
Smoking history missing for 5 patients; 2 from VUMC and 3 from UPMC
Packyears missing from 73 patients; 34 from VUMC and 39 from UPMC
Staged according to p16 result, those with missing p16 results were staged as if p16-positive
Staging information missing for 13 patients, 12 from VUMC and 1 from UPMC
Treatment was missing from 2 patients, 1 from VUMC and 1 from UPMC
Other treatment includes radiation only, chemo only, surgery and chemo, palliative care, immunotherapy, clinical trial protocols
p16 testing results missing from 12 UPMC patients
Abbreviations: VUMC, Vanderbilt University Medical Center; UPMC, University of Pittsburgh Medical Center; IQR, interquartile range; AJCC, American Joint Commission on Cancer